Sunshine Biopharma Files Draft Information Statement
Sunshine Biopharma's draft information statement outlines shareholder authorization for discounted share issuance exceeding 20% of outstanding common stock. The October 13, 2026, authorization covers Series D Warrant exercise-price adjustments and proportional underlying share adjustments following share combinations.